AIMS: Diabetes mellitus is associated with worse outcomes and lower attainment of disease-modifying therapies in patients with heart failure with reduced ejection fraction (HFrEF). This post hoc analysis of TRANSITION compared the patterns of tolerability and uptitration of sacubitril/valsartan in patients with HFrEF stabilized after hospital admission due to acute decompensated HF depending on the presence or absence of diabetes as a co-morbidity. METHODS: TRANSITION, a randomized, open-label study compared sacubitril/valsartan initiation pre-discharge vs. post-discharge (up to14 days) in 991 patients hospitalized for acutely decompensated HFrEF. The impact of diabetes status on tolerability and safety was studied at 10-week and 26-week post-randomization. RESULTS: Among the 991 patients analysed at baseline, 460 (46.4%) had diabetes and exhibited a higher risk profile. At 10 weeks, sacubitril/valsartan target dose (97/103 mg bid) was achieved in a similar proportion of patients in each subgroup, when initiated pre-discharge or post-discharge respectively [diabetes subgroup: 47% (n = 105/226) vs. 50% (n = 115/228); relative risk ratio (RRR), 0.923; P = 0.412; non-diabetes subgroup: 45% (n = 119/267) vs. 51% (n = 133/261); RRR, 0.878; P = 0.155]. The proportions of patients achieving and maintaining either 49/51 mg or 97/103 mg bid [diabetes subgroup: 61.1% (n = 138/226) vs. 67.5% (n = 154/228); RRR, 0.909; P = 0.175; non-diabetes subgroup: 62.9% [n = 168/267] vs 69.3% [n = 181/261]; RRR, 0.906; P = 0.118] or any dose for ≥2 weeks leading to Week 10 [diabetes subgroup: 85% (n = 192/226) vs. 88.2% (n = 201/228); RRR, 0.966; P = 0.356; non-diabetes subgroup: 86.9% (n = 232/267) vs. 90.8% (n = 237/261); RRR, 0.963; P = 0.215] were also similar in each subgroup, when initiated pre-discharge or post-discharge, respectively. At 10 weeks, hypotension and renal dysfunction rates were similar, although hyperkalaemia was higher among patients with diabetes (15.9% vs. 9.5%). The rate of permanent discontinuation due to adverse events was similar in the diabetes and non-diabetes subgroups at 10 weeks, respectively: pre-discharge (7.5% vs. 7.1%) or post-discharge (5.7% vs. 4.2%). Similar patterns of uptitration and tolerability were observed at 26 weeks. Cardiac biomarkers including NT-proBNP (P < 0.005) and hs-TnT (P < 0.005) reduced significantly from baseline levels in both subgroups at Weeks 4 and 10; however, the response was greater among patients without diabetes. Mortality (diabetes vs. non-diabetes subgroups: 3.3% vs 4.0%; P = 0.438) and HF rehospitalization (diabetes vs. non-diabetes subgroups: 36.3% vs. 33.0%; P = 0.295) did not differ between the groups at 26 weeks. CONCLUSIONS: Despite a higher risk profile among patients with diabetes, sacubitril/valsartan initiation either before or shortly after discharge in hospitalized patients with HFrEF resulted in comparable rates of dose up-titration and tolerability as in those without diabetes.

1st Department of Cardiology Poznan University of Medical Sciences Poznan Poland

2nd Department of Medicine Department of Cardiovascular Medicine 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague Czech Republic

Cardio Renal and Metabolic Department Novartis Pharma AG Basel Switzerland

Cardio Renal and Metabolic Department Novartis Pharmaceuticals East Hanover NJ USA

Cardiovascular Department and Cardiology Unit Ospedale Papa Giovanni XXIII Bergamo Italy

Department of Cardiology Hospital Virgen de la Arrixaca University of Murcia Murcia Spain and Centro Nacional de Investigaciones Cardiovasculares Madrid Spain

Department of Cardiology Leipzig University Hospital Leipzig Germany

Department of Internal Medicine 1 University Hospital RWTH Aachen University Aachen DE; and Leeds Institute of Cardio and Metabolic Medicine University of Leeds Leeds UK

Department of Medicine and Population Health Research Institute McMaster University Hamilton Canada

Hospital de Sao Francisco Xavier Lisbon Portugal

See more in PubMed

Seferovic PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, Paulus WJ, Komajda M, Cosentino F, de Boer RA, Farmakis D, Doehner W, Lambrinou E, Lopatin Y, Piepoli MF, Theodorakis MJ, Wiggers H, Lekakis J, Mebazaa A, Mamas MA, Tschope C, Hoes AW, Seferovic JP, Logue J, McDonagh T, Riley JP, Milinkovic I, Polovina M, van Veldhuisen DJ, Lainscak M, Maggioni AP, Ruschitzka F, McMurray JJV. Type 2 diabetes mellitus and heart failure: A position statement from the heart failure Association of the European Society of cardiology. Eur J Heart Fail. 2018. May; 20: 853–872. PubMed

McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo‐Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, Group ESCSD . 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42: 3599–3726. PubMed

Writing Committee M, Members AAJC. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Card Fail. 2022; 28: e1e–167. PubMed

Greene SJ, Butler J, Albert NM, DeVore AD, Sharma PP, Duffy CI, Hill CL, McCague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical therapy for heart failure with reduced ejection fraction: The CHAMP‐HF registry. J Am Coll Cardiol. 2018; 72: 351–366. PubMed

Jefferies JL, Ibrahim NE. Are guidelines merely suggestions? J Am Coll Cardiol. 2018; 72: 367–369. PubMed

Savarese G, Merlo M, Coats AJS, Metra M. Best of European journal of heart failure at the ESC/HFA heart failure congress 2021. Eur J Heart Fail. 2021; 23: 1424–1427. PubMed

Brunner‐La Rocca HP, Linssen GC, Smeele FJ, van Drimmelen AA, Schaafsma HJ, Westendorp PH, Rademaker PC, van de Kamp HJ, Hoes AW, Brugts JJ, Investigators C‐H. Contemporary drug treatment of chronic heart failure with reduced ejection fraction: The CHECK‐HF registry. JACC Heart Fail. 2019; 7: 13–21. PubMed

Atherton JJ, Hickey A. Expert comment: Is medication titration in heart failure too complex? Card Fail Rev. 2017; 3: 25–32. PubMed PMC

Sarma S, Mentz RJ, Kwasny MJ, Fought AJ, Huffman M, Subacius H, Nodari S, Konstam M, Swedberg K, Maggioni AP, Zannad F, Bonow RO, Gheorghiade M, Investigators E . Association between diabetes mellitus and post‐discharge outcomes in patients hospitalized with heart failure: Findings from the EVEREST trial. Eur J Heart Fail. 2013; 15: 194–202. PubMed PMC

Abhinav Sharma SV, Bhatt DL, Connelly KA, Swiggum E, Vaduganathan M, Zieroth S, Butler J. Optimizing foundational therapies in patients with HFrEF. J Am Coll Cardiol Basic Trans Science. 2022. (In press). PubMed PMC

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Investigators P‐H, Committees . Angiotensin‐neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993–1004. PubMed

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, Investigators P‐H . Angiotensin‐neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019; 380: 539–548. PubMed

Senni M, Wachter R, Witte KK, Straburzynska‐Migaj E, Belohlavek J, Fonseca C, Mueller C, Lonn E, Chakrabarti A, Bao W, Noe A, Schwende H, Butylin D, Pascual‐Figal D, Investigators T. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: A subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020. Feb; 22: 303–312. PubMed

Wachter R, Senni M, Belohlavek J, Straburzynska‐Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bohmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noe A, Schwende H, Bao W, Butylin D, Pascual‐Figal D, Investigators T . Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019; 21: 998–1007. PubMed

Pascual‐Figal D, Wachter R, Senni M, Belohlavek J, Noe A, Carr D, Butylin D. Rationale and design of TRANSITION: A randomized trial of pre‐discharge vs. post‐discharge initiation of sacubitril/valsartan. ESC Heart Fail. 2018; 5: 327–336. PubMed PMC

General Assembly of the World Medical Association . World Medical Association declaration of Helsinki: Ethical principles for medical research involving human subjects. J Am Coll Dent. 2014; 81: 14–18. PubMed

Pascual‐Figal D, Wachter R, Senni M, Bao W, Noe A, Schwende H, Butylin D, Prescott MF, Investigators T . NT‐proBNP response to sacubitril/valsartan in hospitalized heart failure patients with reduced ejection fraction: TRANSITION study. JACC Heart Fail. 2020; 8: 822–833. PubMed

Radhoe SP, Veenis JF, Linssen GCM, van der Lee C, Eurlings LWM, Kragten H, Al‐Windy NYY, van der Spank A, Koudstaal S, Brunner‐La Rocca HP, Brugts JJ. Diabetes and treatment of chronic heart failure in a large real‐world heart failure population. ESC Heart Fail. 2022; 9: 353–362. PubMed PMC

Vaduganathan M, Fonarow GC, Greene SJ, DeVore AD, Kavati A, Sikirica S, Albert NM, Duffy CI, Hill CL, Patterson JH, Spertus JA, Thomas LE, Williams FB, Hernandez AF, Butler J. Contemporary treatment patterns and clinical outcomes of comorbid diabetes mellitus and HFrEF: The CHAMP‐HF registry. JACC Heart Fail. 2020; 8: 469–480. PubMed

Benes J, Kotrc M, Jarolim P, Hoskova L, Hegarova M, Dorazilova Z, Podzimkova M, Binova J, Lukasova M, Malek I, Franekova J, Jabor A, Kautzner J, Melenovsky V. The effect of three major co‐morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction. ESC Heart Fail. 2021; 8: 1417–1426. PubMed PMC

Witte KK, Drozd M, Walker AMN, Patel PA, Kearney JC, Chapman S, Sapsford RJ, Gierula J, Paton MF, Lowry J, Kearney MT, Cubbon RM. Mortality reduction associated with beta‐adrenoceptor inhibition in chronic heart failure is greater in patients with diabetes. Diabetes Care. 2018; 41: 136–142. PubMed

Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT‐2 inhibitors in heart failure: Current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019; 8: e013389. PubMed PMC

Pascual‐Figal D, Senni M, Belohlavek J, Butylin D, Noe A, Bao W, Wachter R. Short‐term effect on cardiac biomarkers of initiation of sacubitril/valsartan in hospitalized patients with heart failure and reduced ejection fraction: results of the TRANSITION study. AHA Congress 2018; Chicago, USA; 2018.

Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022; 79: 1757–1780. PubMed

Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, Martinez F, Starling RC, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, Investigators P‐H, Committees . Risk related to pre‐diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: Insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial. Circ Heart Fail. 2016; 9: e002560. PubMed PMC

Morrow DA, Velazquez EJ, DeVore AD, Desai AS, Duffy CI, Ambrosy AP, Gurmu Y, McCague K, Rocha R, Braunwald E. Clinical outcomes in patients with acute decompensated heart failure randomly assigned to sacubitril/valsartan or enalapril in the PIONEER‐HF trial. Circulation. 2019; 139: 2285–2288. PubMed

Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlavek J, Bohm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzalez‐Medina A, Hagege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan O, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz‐Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva‐Cardoso J, Squire IB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC, Investigators P‐H and Coordinators . Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015; 131: 54–61. PubMed

Zile MR, Claggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD. Prognostic implications of changes in N‐terminal pro‐B‐type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2016; 68: 2425–2436. PubMed

Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, Rouleau JL, Swedberg K, Lefkowitz M, Shi VC, Desai AS, McMurray JJV, Solomon SD. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: A post‐hoc analysis from the PARADIGM‐HF trial. Lancet Diabetes Endocrinol. 2017; 5: 333–340. PubMed PMC

Writing C, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, Fonarow GC, Ibrahim NE, Lindenfeld J, Masoudi FA, Motiwala SR, Oliveros E, Patterson JH, Walsh MN, Wasserman A, Yancy CW, Youmans QR. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: Answers to 10 pivotal issues about heart failure with reduced ejection fraction: A report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021; 77: 772–810. PubMed